At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

The FDA has granted approval for Cosette’s Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.

The US Food and Drug Administration (FDA) has rolled out a new framework to spur development of new therapies for rare diseases, marking the latest initiative carried out by the T ...

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare products Regulatory Agency (MHRA) said it would consider allowing ...

Sanofi has signed a global licensing and strategic collaboration agreement with ScionxBio to develop long-acting mRNA therapies using the TERA platform.